



**QUEEN'S
UNIVERSITY
BELFAST**

Formulation of sustained release lipid-based matrix system for vaginal delivery using the twin-screw hot-melt extrusion method

Mohylyuk, V., Hutton, T., Dadou, S., Tian, J., Li, S., Jones, D., & Andrews, G. (2021). *Formulation of sustained release lipid-based matrix system for vaginal delivery using the twin-screw hot-melt extrusion method*. Poster session presented at 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (delayed due to COVID19).

Document Version:
Other version

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2021 The Authors & QUB.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Formulation of sustained release lipid-based matrix system for vaginal delivery using the tween-screw hot-melt extrusion method

V. Mohylyuk^{1,2}, T. Hutton¹, S. Dadou^{1,2}, S. Li^{1,2}, D.S. Jones¹, G.P. Andrews^{1,2}

¹ Pharmaceutical Engineering Group, School of Pharmacy, Queen's University Belfast, BT9 7BL, Northern Ireland

² China Medical University - Queen's University Belfast joint College (CQC), Queen's University Belfast.



PURPOSE

- The development of sustained-release formulations for drugs administered via the vaginal route has the potential to increase treatment efficiency and patient compliance.

- One promising strategy to formulate such dosage forms is the incorporation of microparticles into a bio-adhesive gel.

OBJECTIVE(S)

- To assess feasibility of formulating matrix microparticles using lipid-based carrier systems,
- namely, Syncrowax™ HGLC (hydrophobic insoluble lipid) or Gelucire® 50/13 (G-50/13; hydrophilic lipid),
- with Avicel® PH-101 (MCC) or hypromellose K100M used as diluents.

METHODS

- Model drugs chosen for the study included azidothymidine (AZT) and metronidazole (MTZ).
- **Placebo formulations** prepared by molten-liquid filling of hard gelatine capsules (#3 0.27 ml, Coni-Snap®; Capsugel, Belgium).
- **The drug-loaded microparticles** prepared by twin-screw hot melt extrusion (TS-HME; Microlab L/D 20.1; Rondol Ind. SAS, France) and cutting extrudates with a scalpel.
- Placebo formulations were **screened** for tensile strength, water uptake/ weight loss (WU/WL) and, surface morphology.
- TGA, DSC, polarized-light hot-stage microscopy were used for **characterisation**.
- The **solubility** of each model drug at pH 4.5 was investigated using the shake-flask method.
- The **in-vitro drug release** properties of the formulated microparticles were assessed using USP-II (paddle) in sodium acetate buffer adjusted to pH 4.5 (to simulate vaginal fluid).




Fig. 1. Ternary diagram for investigated placebo (left) and drug-loaded formulations (right).




Fig. 2. Illustration of cracks appeared after heating up and cooling down until room temperature.





Fig. 3. Effect of drug loading on the release from HGLC matrix (left) and Effect of diluents on the drug release from HGLC matrix (right).

RESULTS

- WU/WL testing of placebo formulations allowed to narrow down the experimental plan (Fig. 1)
- HGLC (T_m 48 °C) based particles were prepared with TS-HME at conditions intended to minimize the effect on drug particle size reduction (conveying elements only; 20 rpm) and to maintain full crystallinity of the drug (not more than 62 °C).
- Model drugs AZT (T_m 110 °C) and MTZ (T_m 152 °C)
 - up to 90°C: did not dissolve in excipients (DSC),
 - between 90 and 190 °C: observed dissolution of AZT in G-50/13 (T_m 33°C) as well as MTZ and AZT in HPMC (T_g 57 °C).
- Microscopy observation revealed the development of the cracks during the cooling down of lipid-based formulations (Fig. 2).
- Drug release from particles (approx. 2.2x3 mm) without diluent at 10 and 20% w/w drug load demonstrated slow and incomplete release (Fig. 3 left), that can be explained with percolation threshold.
- Introduction of hydrophilic diluents (10% w/w) allowed to significantly increase drug release rate (Fig. 3 right).
- In accordance with Lapidus-Lordi equation [1], the increase surface area to volume ratio is increasing drug release rate, so preparing sustained release microparticles with additional particle size reduction can be considered.

CONCLUSIONS

- The number of drug-loaded formulations was successfully reduced due to the screening of placebo formulations with WU/WL test.
- Insoluble matrix system based on the insoluble lipid Syncrowax™ HGLC (≥ 80 % w/w) and loaded with model drugs AZT or MTZ was successfully prepared using the twin-screw hot melt extrusion method and provided as sustained release.
- The addition of diluents as Avicel® PH-101 or hypromellose type K100M (at the 10% w/w level) can be used for the adjustment of drug release profile.
- The development of cracks in the Syncrowax™ HGLC lipid matrix during the cooling down stage could be accounted as an additional aspect of drug release facilitation.

REFERENCE

Lapidus, H. and N.G. Lordi, Drug release from compressed hydrophilic matrices. J Pharm Sci, 1968. 57(8): p. 1292-301.



QUEEN'S
UNIVERSITY
BELFAST

SCHOOL OF
PHARMACY